drugset

drugset / Trial / NCT03646864

A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease

NCT03646864 ↗

Phase 1 Completed 28 enrolled Idorsia Pharmaceuticals Ltd.

RandomizedCrossoverQuadruple-blindTreatment

Summary

A study to evaluate the effects of ACT-541468 on respiration in patients with moderate chronic obstructive pulmonary disease

Timeline

Start: 2018-11-15
Primary completion: 2019-09-19
Completion: 2019-09-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Daridorexant	Small molecule	50 mg	Oral

Indications